Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.

Kimmo Kontula1, Päivi J Laitinen, Annukka Lehtonen

  • 1Department of Medicine, University of Helsinki, 00290 Helsinki, Finland. Kimmo.kontula@hus.fi

Cardiovascular Research
|May 26, 2005
PubMed
Summary

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic heart condition causing dangerous arrhythmias. Understanding RyR2 channel dysfunction offers new therapeutic targets for CPVT and other life-threatening heart rhythm disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Multicenter Cohort Study on Beta-Blocker-Free Treatment Strategies for Catecholaminergic Polymorphic Ventricular Tachycardia Patients.

JACC. Clinical electrophysiology·2024
Same author

An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia.

Heart rhythm·2024
Same author

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.

Circulation·2023
Same author

HiPSC-derived cardiomyocyte to model Brugada syndrome: both asymptomatic and symptomatic mutation carriers reveal increased arrhythmogenicity.

BMC cardiovascular disorders·2023
Same author

Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility.

Nature genetics·2022
Same author

Effects of β-blockers on ventricular repolarization documented by 24-hour electrocardiography in long QT syndrome type 2.

Heart rhythm·2022

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Cardiac excitation-contraction coupling relies on calcium ion (Ca2+) influx via L-type calcium channels and Ca2+-induced Ca2+ release from the sarcoplasmic reticulum through ryanodine receptors (RyR2).
  • RyR2 channels interact with regulatory proteins like FKBP12.6 and calsequestrin 2 (CASQ2), and their function is modulated by catecholamines and protein kinase A-mediated phosphorylation.
  • Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited, malignant arrhythmia disorder triggered by physical or emotional stress, often presenting with sudden death in young individuals.

Purpose of the Study:

  • To elucidate the molecular pathogenesis of CPVT, focusing on the role of RyR2 channel dysfunction.
  • To explore potential mechanisms underlying inappropriate RyR2 channel 'leakiness' in CPVT.
  • To identify novel therapeutic strategies for CPVT and other life-threatening arrhythmias.

Related Experiment Videos

Main Methods:

  • Review of molecular mechanisms of cardiac excitation-contraction coupling.
  • Analysis of genetic mutations in RyR2 and CASQ2 genes associated with CPVT.
  • Investigation of altered RyR2 channel activity, phosphorylation, and interactions with regulatory proteins.

Main Results:

  • Mutations in RyR2 (autosomal dominant) and CASQ2 (autosomal recessive or dominant) are causative for CPVT.
  • Inappropriate RyR2 channel 'leakiness' is implicated in CPVT pathogenesis.
  • Potential mechanisms include increased basal RyR2 activity, altered phosphorylation, defective protein interactions (FKBP12.6, CASQ2), or abnormal Ca2+ activation.

Conclusions:

  • Understanding RyR2 channel dysfunction is critical for CPVT pathogenesis.
  • Novel antiarrhythmic drug development targeting RyR2 is a promising avenue.
  • Therapeutic approaches for CPVT may inform treatments for arrhythmias in ischemia and heart failure.